Serrated Colorectal Cancer: The Road Less Travelled?

Siegel, 2019, Cancer statistics, 2019, CA Cancer J. Clin, 69, 7, 10.3322/caac.21551 Fearon, 1990, A genetic model for colorectal tumorigenesis, Cell, 61, 759, 10.1016/0092-8674(90)90186-I Jass, 2001, Serrated route to colorectal cancer: back street or super highway?, J. Pathol, 193, 283, 10.1002/1096-9896(200103)193:3<283::AID-PATH799>3.0.CO;2-9 Vogelstein, 1988, Genetic alterations during colorectal-tumor development, N Engl J. Med, 319, 525, 10.1056/NEJM198809013190901 Jass, 1992, Sialic acid and epithelial differentiation in colorectal polyps and cancer--a morphological, mucin and lectin histochemical study, Pathology, 24, 233, 10.3109/00313029209068874 Snover, 2011, Update on the serrated pathway to colorectal carcinoma, Hum. Pathol., 42, 1, 10.1016/j.humpath.2010.06.002 IJspeert, 2015, Serrated neoplasia-role in colorectal carcinogenesis and clinical implications, Nat. Rev. Gastroenterol. Hepatol., 12, 401, 10.1038/nrgastro.2015.73 Kane, 1997, Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines, Cancer Res., 57 Cunningham, 1998, Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability, Cancer Res., 58, 3455 Herman, 1998, Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma, Proc. Natl. Acad. Sci. U S A., 95, 6870, 10.1073/pnas.95.12.6870 Jass, 2007, Classification of colorectal cancer based on correlation of clinical, morphological and molecular features, Histopathology, 50, 113, 10.1111/j.1365-2559.2006.02549.x Bettington, 2013, The serrated pathway to colorectal carcinoma: current concepts and challenges, Histopathology, 62, 367, 10.1111/his.12055 Garcia-Solano, 2010, Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma, Hum. Pathol., 41, 1359, 10.1016/j.humpath.2010.04.002 Rex, 2012, Serrated lesions of the colorectum: review and recommendations from an expert panel, Am. J. Gastroenterol, 107, 1315, 10.1038/ajg.2012.161 Makinen, 2001, Colorectal carcinoma associated with serrated adenoma--prevalence, histological features, and prognosis, J Pathol, 193, 286, 10.1002/1096-9896(2000)9999:9999<::AID-PATH800>3.0.CO;2-2 Tuppurainen, 2005, Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer, J. Pathol., 207, 285, 10.1002/path.1850 Schlicker, 2012, Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines, BMC. Med. Genomics, 5, 66, 10.1186/1755-8794-5-66 Sadanandam, 2013, A colorectal cancer classification system that associates cellular phenotype and responses to therapy, Nat. Med., 19, 619, 10.1038/nm.3175 Marisa, 2013, Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value, PLoS. Med., 10, 10.1371/journal.pmed.1001453 De Sousa, 2013, Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions, Nat. Med., 19, 614, 10.1038/nm.3174 Budinska, 2013, Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer, J. Pathol., 231, 63, 10.1002/path.4212 Roepman, 2014, Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition, Int. J. Cancer, 134, 552, 10.1002/ijc.28387 Isella, 2015, Stromal contribution to the colorectal cancer transcriptome, Nat. Genet., 47, 312, 10.1038/ng.3224 Guinney, 2015, The consensus molecular subtypes of colorectal cancer, Nat. Med., 21, 1350, 10.1038/nm.3967 Fessler, 2016, TGFbeta signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype, EMBO. Mol. Med., 8, 745, 10.15252/emmm.201606184 Fessler, 2016, Colorectal cancer subtypes: developmental origin and microenvironmental regulation, Trends Cancer, 2, 505, 10.1016/j.trecan.2016.07.008 Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N. Engl. J. Med., 364, 2517, 10.1056/NEJMoa1104621 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N. Engl. J. Med., 372, 311, 10.1056/NEJMoa1411087 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 Carragher, 2010, V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a, EMBO. Mol. Med., 2, 458, 10.1002/emmm.201000099 Rad, 2013, A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention, Cancer Cell, 24, 15, 10.1016/j.ccr.2013.05.014 Nakanishi, 2018, Simultaneous loss of both atypical protein kinase C genes in the intestinal epithelium drives serrated intestinal cancer by impairing immunosurveillance, Immunity, 49, 1132, 10.1016/j.immuni.2018.09.013 Wang, 2003, BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair, Cancer Res., 63, 5209 Kambara, 2004, BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum, Gut, 53, 1137, 10.1136/gut.2003.037671 Koinuma, 2004, Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas, Int. J. Cancer, 108, 237, 10.1002/ijc.11523 Minoo, 2007, Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis, J. Pathol., 212, 124, 10.1002/path.2160 Toyota, 1999, CpG island methylator phenotype in colorectal cancer, Proc. Natl. Acad. Sci. U S A., 96, 8681, 10.1073/pnas.96.15.8681 Weisenberger, 2006, CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer, Nat. Genet., 38, 787, 10.1038/ng1834 Park, 2003, Frequent CpG island methylation in serrated adenomas of the colorectum, Am. J. Pathol., 162, 815, 10.1016/S0002-9440(10)63878-3 Tao, 2019, Aging-like spontaneous epigenetic silencing facilitates Wnt activation, stemness, and Braf(V600E)-induced tumorigenesis, Cancer Cell, 35, 315, 10.1016/j.ccell.2019.01.005 Lynch, 2015, Milestones of Lynch syndrome: 1895-2015, Nat. Rev. Cancer, 15, 181, 10.1038/nrc3878 Vleugels, 2018, Endoscopic detection rate of sessile serrated lesions in Lynch syndrome patients is comparable with an age- and gender-matched control population: case-control study with expert pathology review, Gastrointest. Endosc., 87, 1289, 10.1016/j.gie.2017.11.034 Andersen, 2008, Sessile serrated polyps of the colorectum are rare in patients with Lynch syndrome and in familial colorectal cancer families, Fam. Cancer, 7, 157, 10.1007/s10689-007-9163-7 Stefanius, 2011, Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma, Histopathology, 58, 679, 10.1111/j.1365-2559.2011.03821.x Huang, 2011, The clinical significance of serrated polyps, Am. J. Gastroenterol., 106, 229, 10.1038/ajg.2010.429 Bennecke, 2010, Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis, Cancer Cell, 18, 135, 10.1016/j.ccr.2010.06.013 Bond, 2018, Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia, Epigenetics, 13, 40, 10.1080/15592294.2017.1411446 Lannagan, 2019, Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis, Gut, 68, 684, 10.1136/gutjnl-2017-315920 Sakamoto, 2017, BRAF(V600E) cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis, eLife, 6, 10.7554/eLife.20331 Balbinot, 2018, The Cdx2 homeobox gene suppresses intestinal tumorigenesis through non-cell-autonomous mechanisms, J. Exp. Med., 215, 911, 10.1084/jem.20170934 Cancer Genome Atlas, 2012, Comprehensive molecular characterization of human colon and rectal cancer, Nature, 487, 330, 10.1038/nature11252 Richman, 2009, KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial, J. Clin. Oncol., 27, 5931, 10.1200/JCO.2009.22.4295 Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J. Clin. Oncol., 28, 466, 10.1200/JCO.2009.23.3452 Kopetz, 2015, Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer, J. Clin. Oncol., 33, 4032, 10.1200/JCO.2015.63.2497 Prahallad, 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, Nature, 483, 100, 10.1038/nature10868 Corcoran, 2012, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib, Cancer Discov., 2, 227, 10.1158/2159-8290.CD-11-0341 Mao, 2013, Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents, Clin. Cancer Res., 19, 657, 10.1158/1078-0432.CCR-11-1446 Chappell, 2011, Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health, Oncotarget., 2, 135, 10.18632/oncotarget.240 Flaherty, 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, N Engl J Med, 367, 1694, 10.1056/NEJMoa1210093 Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma, N Engl J Med, 367, 107, 10.1056/NEJMoa1203421 Rusconi, 2012, RAS/RAF/MEK inhibitors in oncology, Curr. Med. Chem., 19, 1164, 10.2174/092986712799320510 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Llosa, 2019, Intratumoral adaptive immunosuppression and Type 17 immunity in mismatch repair proficient colorectal tumors, Clin. Cancer Res., 25, 5250, 10.1158/1078-0432.CCR-19-0114 Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study, Lancet Oncol., 18, 1182, 10.1016/S1470-2045(17)30422-9 Tauriello, 2018, TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis, Nature, 554, 538, 10.1038/nature25492 Liao, 2019, KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer, Cancer Cell, 35, 559, 10.1016/j.ccell.2019.02.008 Barker, 2014, Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration, Nat Rev. Mol. Cell Biol., 15, 19, 10.1038/nrm3721 Medema, 2011, Microenvironmental regulation of stem cells in intestinal homeostasis and cancer, Nature, 474, 318, 10.1038/nature10212 Tong, 2017, Degree of tissue differentiation dictates susceptibility to BRAF-driven colorectal cancer, Cell Rep., 21, 3833, 10.1016/j.celrep.2017.11.104 Thibodeau, 1993, Microsatellite instability in cancer of the proximal colon, Science, 260, 816, 10.1126/science.8484122 Shin, 2017, Sessile serrated adenoma; the hard-to-catch culprit of interval cancer, Clin. Endosc., 50, 215, 10.5946/ce.2017.052 Lee, 2017, Clinical and biological features of interval colorectal cancer, Clin. Endosc., 50, 254, 10.5946/ce.2016.115 Lee, 2017, Right versus left colon cancer biology: integrating the consensus molecular subtypes, J. Natl. Compr. Canc. Netw., 15, 411, 10.6004/jnccn.2017.0038 Missiaglia, 2014, Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features, Ann. Oncol., 25, 1995, 10.1093/annonc/mdu275 Moretto, 2016, Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer, Oncologist, 21, 988, 10.1634/theoncologist.2016-0084 Vasaikar, 2019, Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities, Cell, 177, 1035, 10.1016/j.cell.2019.03.030 Reina-Campos, 2019, The dual roles of the atypical protein Kinase Cs in cancer, Cancer Cell, 36, 218, 10.1016/j.ccell.2019.07.010 Moscat, 2016, p62 in cancer: signaling adaptor beyond autophagy, Cell, 167, 606, 10.1016/j.cell.2016.09.030 Nakanishi, 2016, Control of Paneth cell fate, intestinal inflammation, and tumorigenesis by PKClambda/iota, Cell Rep., 16, 3297, 10.1016/j.celrep.2016.08.054 Wald, 2011, Aberrant expression of the polarity complex atypical PKC and non-muscle myosin IIA in active and inactive inflammatory bowel disease, Virchows. Arch., 459, 331, 10.1007/s00428-011-1102-1 Ma, 2013, Control of nutrient stress-induced metabolic reprogramming by PKCzeta in tumorigenesis, Cell, 152, 599, 10.1016/j.cell.2012.12.028 Galvez, 2009, Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo, Mol. Cell. Biol., 29, 104, 10.1128/MCB.01294-08 Wood, 2007, The genomic landscapes of human breast and colorectal cancers, Science, 318, 1108, 10.1126/science.1145720 Llado, 2015, Repression of intestinal stem cell function and tumorigenesis through direct phosphorylation of beta-catenin and Yap by PKCzeta, Cell. Rep., 10, 740, 10.1016/j.celrep.2015.01.007 Shelton, 2018, The secretion of miR-200s by a PKCzeta/ADAR2 signaling axis promotes liver metastasis in colorectal cancer, Cell Rep., 23, 1178, 10.1016/j.celrep.2018.03.118